APPLICATION OF COBRA VENOM FACTORS IN LIFE SCIENCES
Keywords:
Cobra venom factor, Complement, Complement alternative pathway, Endothelial cells, InflammationAbstract
Complement is an important part of the immune system and plays an important role in the body's natural defense and immune regulation. Excessive activation of complement can cause inflammation and tissue damage. In particular, excessive activation of the alternative complement pathway plays an important role in the occurrence and development of a series of diseases and symptoms. Role. Cobra venom factor, a specific activating protein of the complement alternative pathway isolated from cobra venom, has played an important role in complement-related research use. Here is a review of the application of cobra venom factors in life sciences.References
[1] Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res, 2010, 20: 34-50
[2] Merle SH, Noah R, R, Halbwachs-Mecarelli L, L, et al. Complement system part II: role in immunity. Front Immunol, 2015, 6: 257
[3] Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov, 2010, 9: 43-56
[4] Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol, 2010, 11: 785-97
[5] Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol, 2006, 176: 1305-10
[6] Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev, 2008, 223: 300-16
[7] Ballow M, Cochrane CG. Two anticomplement factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol, 1969, 103: 944-52
[8] Müller-Eberhard HJ, Fjellstrom KE. Isolation of the anticopmlementary protein from cobra venom and its mode of action on C3. J Immunol, 1971, 107: 1666-72
[9] Pepys MB, Tompkins C, Smith AD. An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A. J Immunol Methods, 1979,30: 105-17
[10] von Zabern I, Hinsch B, Przyklenk H, et al. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology, 1980, 157: 499-514
[11] Eggertsen G, Lind P, Sj?quist J. Molecular characterization of the complement activating protein in the venom of the indian cobra (Naja n. siamensis). Mol Immunol, 1981, 18: 125-33
[12] Takahashi H, Hayashi K. Purification and characterzation of anticomplement factor (cobra venom factor) from the Naja naja atra venom. Biochim Biophys Acta, 1982, 701: 102-10
[13] Vogel CW, Müller-Eberhard HJ. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods, 1984, 73: 203-20
[14] Sun QY, Lu QM, Wang WY, et al. A highly active anticomplement factor from the venom of Naja kaouthia. Acta Biochem Biophy Sin, 2001, 33: 483-8
[15] Vogel CW, Bredehorst R, Fritzinger DC, et al. Structure and function of cobra venom factor, the complement- activating protein in cobra venom. Adv Exp Med Biol, 1996, 391: 97-114
[16] Vogel CW, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon, 2010, 56: 1198-222
[17] Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol, 1996, 61: 201-83
[18] Janssen BJ, Gomes L, Koning RI, et al. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J, 2009, 28: 2469-78
[19] Laursen NS, Andersen KR, Braren I, et al. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J, 2011, 30: 606- 16
[20] Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol, 2009, 46: 2774-83
[21] Takano T, Elimam H, Cybulsky AV. Complement - mediated cellular injury. Semin Nephrol, 2013, 33: 586- 601
[22] Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med, 2013, 24: 496-502
[23] Song WC. Crosstalk between complement and toll-like receptors. Toxicol Pathol, 2012, 40: 174-82
[24] Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol, 2013, 735: 1-22
[25] Wang Cai'e, Sun Qianyun, Li Min, wait. Snake venom anti-complement protein atrase B inhibition Platelet aggregation induced by complement activation. Chinese Pharmacological Bulletin, 2 009, 25: 1205-9
[26] Li Min, Shen Liangxian, Zhang Xiangyan, wait. Two anti-complement proteins cause lipopolysaccharide Comparative study on the protective effect of acute lung injury. Chinese Pharmacological Bulletin, 2012, 28: 521-6
[27] Sun Qianyun, Li Min, Ye Qiaoling, wait. Activation of the complement alternative pathway leads to endothelial cell activation and damage. Chinese Pharmacological Bulletin, 2012, 28: 925-9
[28] Li Hongling, Sun Qianyun, Li Min, wait. Complement alternative pathway activation products stimulate endothelium cellular NF -κB, p38 MAPK, JAK 2 pathway activation and inhibitors intervention research. Chinese Journal of Cell Biology, 201 3, 35: 836-41
[29] Li Min, Sun Qianyun, Zhao Qiong, wait. Excessive activation of complement alternative pathway affects coagulation in vivo blood function. Chinese Pharmacological Bulletin, 2014, 30: 39-44
[30] Lu Qingyu, Li Min, Sun Qianyun. Activation of complement alternative pathway induces endothelial cell fibrinolysis Research on expression changes and intervention of coagulation-related molecules. Chinese Pharmacological Bulletin, 2015, 31: 1142-6
[31] O’Connell PJ, Cunningham A, d’Apice AJ. Xenotrans- plantation: its problems and potential as a clinical procedure. Transplant Rev, 2000, 14: 18-40
[32] Cooper DK, Ekser B, Tector AJ. Immunobiological barriers to xenotransplantation. Int J Surg, 2015 [Epub ahead of print]